Joint Clinical Assessment (JCA) And Potential Consequences For The Evaluation Of Gene Therapies
In October 2019, Galderma announced that the U.S. FDA approved AKLIEF® (trifarotene) Cream, 0.005% for the…
Danielle Pillsbury2024 年 6 月 17 日
Accelerating a drug launch with value communication technology and an integrated workflow
With early approvals for a targeted cancer drug in Brazil and Argentina, this global pharmaceutical…
Jim Gallagher2023 年 10 月 2 日
Using customer engagement technology to create value communication tools for ABILIFY MAINTENA® (aripiprazole)
Otsuka identified several weaknesses in their existing workflow for developing value communication tools. In particular,…
Jim Gallagher2023 年 10 月 2 日
Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial
Our client was developing a new anti-viral drug for a rare, life-threatening viral infection that…
Danielle Pillsbury2023 年 4 月 17 日
Using Real World Evidence to Inform Treatment Guidelines
Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…
Danielle Pillsbury2023 年 4 月 5 日
Using Real Word Evidence to Enhance Drug Development
Real-world evidence (RWE) has emerged as an increasingly important tool in the drug development process,1…
Danielle Pillsbury2023 年 4 月 5 日
Agent-Based Model Predicts Impact of Monoclonal Antibody Treatment, Prophylaxis & Vaccines on Viral Transmission during Pandemic
Agent-based models focus on the heterogeneous behavior of individual agents and their interactions with one…
Danielle Pillsbury2023 年 3 月 2 日
The Scary Future of Rare Disease Management
In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…
Jim Gallagher2021 年 9 月 23 日
